Skip to main content
. Author manuscript; available in PMC: 2022 Apr 18.
Published in final edited form as: Gut. 2020 Aug 26;70(4):796–802. doi: 10.1136/gutjnl-2020-322129

Table 3.

Current non-IBD FDA-approved indications for biological agents used in IBD management

Biologics Agent Approved for the following non-IBD IMIDs
Anti-TNF Infliximab RA, SpA, PsA, Pso
Adalimumab RA, JIA, PsA, SpA, hidradenitis suppurativa, Pso, uveitis
Certolizumab pegol RA, PsA, SpA, Pso
Golimumab RA, PsA, SpA
Anti-integrin Vedolizumab None
Natalizumab Multiple sclerosis
JAK inhibitors Tofacitinib RA, PsA
IL-12/23 Ustekinumab Pso, PsA

FDA, Food and Drug Administration; IL, interleukin; IMIDs, immune-mediated inflammatory diseases; JAK, Janus kinase; JIA, juvenile idiopathic arthritis; PsA, psoriatic arthritis; Pso, psoriasis; RA, rheumatoid arthritis; SpA, axial spondyloarthropathy; TNF, tumour necrosis factor.